FMR LLC and Abigail P. Johnson report beneficial ownership of 2,054,127.49 shares of First Tracks Biotherapeutics Inc. common stock, representing 5.9% of the class. FMR LLC has sole voting power over 2,053,988.00 shares and sole dispositive power over 2,054,127.49 shares, with no shared voting or dispositive power reported.
Abigail P. Johnson is shown with sole dispositive power over 2,054,127.49 shares and no voting power, reflecting her control relationship with FMR LLC. One or more other persons may receive dividends or sale proceeds from these shares, but each such interest is stated to be under five percent of the outstanding common stock.
STONE BENJAMIN reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. granted Chief Business Officer Benjamin Stone 60,492 performance-based restricted stock units (PSUs) on August 2, 2026, each representing one share of common stock. The PSUs were earned upon certified achievement of performance criteria and vest over two years: 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service on each vesting date. Following this award, Stone directly holds 77,159 PSUs.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. granted its Chief Medical Officer, Paul F. Lizzul, 60,492 performance stock units (PSUs) on August 2, 2026, after achievement of performance criteria certified by the Compensation Committee. Each PSU represents a conditional right to one share of common stock. The PSUs vest and settle over two years, with 50% vesting on August 2, 2027 and 50% on July 1, 2028, subject to his continued service, bringing his total PSUs to 77,159.
First Tracks Biotherapeutics, Inc. President and CEO Daniel Faga reported an acquisition of 193,576 performance stock units (PSUs), each representing a conditional right to receive one share of common stock. These PSUs were earned upon achievement of performance criteria certified on August 2, 2026, and vest 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service. Following this award, Faga holds 387,156 PSUs in total.
BlackRock, Inc. reported a passive ownership position in First Tracks Biotherapeutics Inc. common stock. BlackRock beneficially owns 1,919,376 shares, representing 5.5% of the class. It has sole voting power over 1,886,631 shares and sole dispositive power over all 1,919,376 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of First Tracks Biotherapeutics’ outstanding common shares.
First Tracks Biotherapeutics, Inc. entered into a new sublease on June 15, 2026 with AnaptysBio, Inc. for approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, California.
The initial sublease term runs for 12 months, with an option to extend for up to an additional period ending no later than April 4, 2028, if the company gives at least three months’ prior written notice. The company may also terminate the sublease at any time during the term with three months’ prior written notice.
Monthly payments under the sublease equal the Basic Rent and Additional Rent AnaptysBio owes under the existing master lease, and the company is responsible for charges for services it requests. The sublease is subordinate to the master lease and will end if AnaptysBio’s lease or right to possess the premises terminates.
First Tracks Biotherapeutics director Rita Jain exercised equity awards to acquire additional common shares. On June 15, 2026, she acquired 7,330 shares of common stock through the exercise or conversion of restricted stock units at no cash exercise price, increasing her direct holdings to 19,194 shares.
The filing shows two RSU tranches of 1,300 and 6,030 units converting into common stock. Footnotes explain that each RSU represents a contingent right to receive one share upon settlement for no consideration, with vesting tied to continued service through June 15, 2026.
First Tracks Biotherapeutics director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026, he acquired 6,030 shares of Common Stock at a reported price of $0.00 per share through an RSU conversion. Following this transaction, he directly holds 37,652 shares of Common Stock. The RSU award represented a contingent right to receive one share of Common Stock per unit upon settlement for no consideration.
First Tracks Biotherapeutics director John A. Orwin exercised restricted stock units to acquire 6,030 shares of Common Stock. The derivative exercise occurred on June 15, 2026 at an exercise price of $0.00 per share, increasing his direct holdings to 16,695 Common Stock shares.
The transaction reflects settlement of an RSU award, where each RSU represented a contingent right to receive one share of Common Stock for no consideration. The RSUs vested 100% on June 15, 2026, subject to his continued service to the company on that vesting date.
First Tracks Biotherapeutics director Ware J. Anthony exercised restricted stock units into common shares. On June 15, 2026, 6,030 Restricted Stock Units converted into 6,030 shares of Common Stock at no cost upon vesting. Following this settlement, he directly holds 15,660 common shares. No shares were sold in this filing.